Biosimilars in the management of chronic inflammatory diseases: The Dutch experience
Authors:
- 1 January 2019
- journal article
- review article
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 30 (Suppl 1) , 76-81
Abstract
These days, the use of biosimilars for the treatment of bio-naive patients is well established. However, the transition of patients being treated with a bio-originator to its biosimilar is still a topic of discussion. The main issue is which approach to use when initiating the non-medical transition. The first real-world examples contain both mandatory and non-mandatory approaches, resulting in a variety of acceptance and discontinuation rates. At this moment a non-mandatory approach, based on shared decision making, is preferred by international guidelines and the Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. However, clear definitions of mandatory and non-mandatory are lacking, as a result of which these terms may be wrongly used in some studies. This article aims to provide an overview of transition approaches used in the Netherlands, and how the approach used relates to acceptance and discontinuation rates of the biosimilar.Keywords
This publication has 19 references indexed in Scilit:
- Consensus-based recommendations for the use of biosimilars to treat rheumatological diseasesAnnals of the Rheumatic Diseases, 2018
- The nocebo effect challenges the non-medical infliximab switch in practiceEuropean Journal of Clinical Pharmacology, 2018
- Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort studyAlimentary Pharmacology & Therapeutics, 2017
- Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar InfliximabArthritis & Rheumatology, 2017
- Treatment Outcomes with Biosimilars: Be Aware of the Nocebo EffectRheumatology and Therapy, 2017
- Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2017
- Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort StudyJournal of Crohn's and Colitis, 2016
- Biosimilars for the management of rheumatoid arthritis: economic considerationsExpert Review of Clinical Immunology, 2015
- The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European CountriesAdvances in Therapy, 2015
- The nocebo effect: patient expectations and medication side effectsPostgraduate Medical Journal, 2013